ArticleJournal for immunotherapy of cancer2022

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.

Rachel E Sanborn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.